The firm intends to use the proceeds for working capital, general corporate purposes and the potential repayment of indebtedness.
The firm announced in October that had entered into an agreement with Jefferies to sell up to $50 million in shares from time to time.
The firm will use the funds to commercialize its newly cleared molecular diagnostics platform and gastrointestinal pathogen panel test.
The company said it intends to use the proceeds for working capital and corporate purposes, including capital expenditures, R&D, clinical trials, and more.
The move signals a shift from the startup's original strategy of creating a cryptocurrency to compensate donors of genomic and clinical data.
The company plans to use parts of the proceeds from the offering to pay for the recent settlement with Illumina.
Biocept closed a $14.8 million public offering earlier this year and recently reported ending the second quarter with $2.6 million in cash and cash equivalents.
The firm will sell more than 14 million shares of its common stock for $4.25 per share.
The firm did not disclose how many shares it planned to sell or how much money it expects to raise.
The filing follows the firm's recent close of a $2 million non-convertible debt instrument and CE marking for its tuberculosis test.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.